TIDMANA
Ananda Developments PLC
08 December 2022
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda's ambition is to be a leading UK grower and manufacturer
of consistent, high-quality medical cannabis for UK patients.
Medical Cannabis Research Roundup
Issue Fourteen
Summary:
-- Cannabis-based oral spray to treat uncontrolled cancer pain - a pilot study.
-- Can an individual's genetic footprint predict the analgesic effects of cannabis?
-- Could CBD keep anxiety away?
CANNABIS-BASED ORAL SPRAY TO TREAT UNCONTROLLED CANCER PAIN - A
PILOT STUDY.
Scientists from The University of Sydney have tested the safety,
tolerance, metabolism and analgesic effects of an oral spray
containing a cannabis-based medicine in cancer patients with severe
and uncontrolled pain despite opioid treatment. The oral spray had
97.5% THC and CBD; the remaining consisted of other cannabinoids in
a solvent and with peppermint oil flavour.
The dosing was divided into two different stages. Stage I of the
study aimed to determine the cannabinoid levels in the blood of
cancer patients with controlled pain. On day one, five participants
were given 2.5 mg THC and 2.5 mg of CBD (two actuations of the
spray), and on day two, the doses increased to 7.5 mg THC and 7.5
mg of CBD. The oral spray was administered inside either cheek.
Blood samples were collected at different times during the
study.
Stage II of the study ran for 30 days and included 25
individuals diagnosed with advanced incurable cancer and
uncontrolled pain. They were administered one, two or three
actuations every 4-8 hours (unless asleep) for six days. Only 22
participants completed stage II of the study.
Stage I results reported acceptable THC and CBD levels in blood
with safety, tolerability, and analgesic effect. Likewise, stage II
results showed that the administration of the cannabis-based oral
spray was safe, well tolerated, and improved pain management.
Additionally, patients reported overall benefits such as more
appetite, sleep quality and feeling more energetic and
functional.
In conclusion, the cannabis-based oral spray tested in this
pilot study proved to be safe, tolerable and have analgesic
efficacy in patients suffering from incurable cancers with
uncontrolled pain.
CAN AN INDIVIDUAL'S GENETIC FOOTPRINT PREDICT THE ANALGESIC
EFFECTS OF CANNABIS?
Researchers from the Italian Society of Cannabis Research
investigated if the significant person-to-person differences in
response to cannabis are due to genetic polymorphisms, which are
variants of a particular DNA sequence among individuals.
The observational study included 564 patients treated with
cannabis for chronic pain. All patients were tested for genetic
variants, and samples were obtained with cheek swaps. The decrease
in pain was approximately 20% during the first month, a further 50%
in the third month and an additional 43% after one year. However,
the analgesic and unwanted side effects observed were very variable
among individuals, linked to variations in particular DNA sequences
of the genes ABCB1, TRPV1 and UGT2B7.
Based on these results, researchers could group the participants
into good responders, intermediate responders and poor or
non-responders. This study, therefore, supports that the genetic
footprint of an individual can define their positive or negative
response to cannabis.
COULD CBD KEEP ANXIETY AWAY?
Researchers from The University of São Paulo and other
collaborators established a three-month observational clinical
study to investigate if the anti-anxiety effects of oral CBD (300
mg) administered for 28 days were maintained after the participants
discontinued taking CBD.
Anxiety is the most common mental health disorder worldwide, and
current treatment with anxiolytic and antidepressant drugs only
works for 40%-60% of patients, causing multiple unwanted effects.
The researchers surveyed 300 Brazilian frontline healthcare workers
during the COVID-19 pandemic weekly during the first month and
weeks eight and 12. Of the 300 participants, 71 from the CBD group
and 79 from the control group completed the three-month study.
The study proved that frontline healthcare workers taking CBD
daily for 28 days had beneficial effects on anxiety, emotional
exhaustion and depression symptoms which lasted for up to a month
after discontinuing the treatment.
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
Chief Executive Officer
Melissa Sturgess
Investor Relations ir@anandadevelopments.com
Jeremy Sturgess-Smith
PETERHOUSE CAPITAL LIMITED
Corporate Finance
Mark Anwyl
Corporate Broking
Lucy Williams
Duncan Vasey +44 (0)20 7469 0930
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company creating
UK-based operations to grow and provide carbon zero, consistent,
medical cannabis for the UK and international markets.
For more information, please visit:
https://anandadevelopments.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFDLFBLLLXFBV
(END) Dow Jones Newswires
December 08, 2022 02:00 ET (07:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Apr 2024 to May 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From May 2023 to May 2024